electroCore, Inc.
NASDAQ:ECOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
electroCore, Inc.
NASDAQ:ECOR
|
US |
|
Anhui Conch Cement Co Ltd
SSE:600585
|
CN |
|
TradeGo FinTech Ltd
HKEX:8017
|
HK |
|
Molson Coors Canada Inc
TSX:TPX.A
|
CA |
|
Blue Moon Group Holdings Ltd
HKEX:6993
|
CN |
|
D
|
Demire Deutsche Mittelstand Real Estate AG
XETRA:DMRE
|
DE |
|
N
|
Noble Development PCL
SET:NOBLE
|
TH |
|
Bactiguard Holding AB
STO:BACTI B
|
SE |
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
US |
|
Asante Inc
TSE:6073
|
JP |
|
O
|
OrganoClick AB
STO:ORGC
|
SE |
|
SonoScape Medical Corp
SZSE:300633
|
CN |
|
A
|
AptaBio Therapeutics Inc
KOSDAQ:293780
|
KR |
|
Fujian Wanchen Biotechnology Co Ltd
SZSE:300972
|
CN |
|
Kshitij Polyline Ltd
NSE:KSHITIJPOL
|
IN |
|
Edifier Technology Co Ltd
SZSE:002351
|
CN |
|
K
|
Kerjaya Prospek Group Bhd
KLSE:KERJAYA
|
MY |
|
Cosco Shipping International (Singapore) Co Ltd
SGX:F83
|
SG |
electroCore, Inc.
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
